Alaska Nurse Practitioner Association

Case Studies in Cardiovascular Disease Prevention and People with HIV

CE Information
1.0 CE credit (0.5 pharmacology)
Completion Time
1 hour
Available Until
November 6, 2025
Posted By
American Academy of CME
American Academy of CME American Academy of CME
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Adult and Women's Health
Subspecialties
HIV/AIDS and Infectious Disease
Clinical Topics
AIDS/HIV, Cardiovascular Disease, Infectious Disease, and Primary Care

By participating in this webinar, you will have the opportunity to enhance patient care by gaining a deeper understanding of the unique cardiovascular risks faced by people with HIV. With this knowledge, you’ll be better equipped to work with your care team to tailor preventive strategies, leading to improved patient outcomes and more comprehensive care. Additionally, the webinar will help you stay current with best practices in the ever-evolving field of HIV care. By learning about the latest effective primary prevention measures, you can ensure that your clinical practices are aligned with current guidelines. Lastly, the webinar emphasizes team-based care, offering valuable insights on collaborating with multidisciplinary teams to optimize care coordination and support for patients with HIV.

What You Can Expect:

  1. Practical Application of the Science: Our expert faculty educators will guide you through this engaging and informative program, and offer suggestions on how you can apply the latest science to patient care.
  2. Patient-Centered Care: Learn from faculty who are directly involved in patient care about strategies for providing compassionate care that addresses individuals’ unique needs and challenges.
  3. Team Focused: Explore how HIV clinicians from multiple professions are collaborating to optimize patient care.

Learning Objectives

After participating in the activity, learners should be better able to:
  • Describe CV disease and its unique features among people with HIV.
  • Identify effective primary prevention strategies for CV specifically tailored for people with HIV.
  • Discuss team-based approaches for implementing primary prevention of CV disease in the HIV population.

Speakers

Virginia Triant
Virginia Triant MD, MPH, FIDSA

Physician and Clinical Investigator
Divisions of Infectious Diseases and General Internal Medicine
Massachusetts General Hospital

Virginia Triant, MD, MPH, FIDSA, is a physician and clinical investigator in the Divisions of Infectious Diseases and General Internal Medicine at Massachusetts General Hospital dedicated to studying the intersection between HIV and aging-related chronic disease complications of HIV. Her team is currently investigating how to optimize cardiovascular risk prediction strategies in people living with HIV. Dr. Triant is an active infectious diseases clinician in the inpatient and outpatient setting. She co-directs the Age Positively Program at MGH, serves as an Associate Director for the Harvard University CFAR Developmental and Mentoring Core, and serves on the HIV Medicine Association Board of Directors. Through her research and clinical care, Dr. Triant seeks to enhance care for people aging with HIV by reducing disparities and improving long-term chronic disease outcomes.

Kathleen Fitch
Kathleen Fitch MSN, FNP-BC

SPIRE Project Director, Mongan Institute Center for Aging and Serious Illness
Division of Palliative Care and Geriatric Medicine
Massachusetts General Hospital

Kathleen Fitch, MSN, FNP-BC, is a Clinical Research Nurse Practitioner in the Massachusetts General Hospital Metabolism Unit. She earned her Master of Science in Nursing at the MGH Institute of Health Professions. During the past 15 years as an investigator, Ms. Fitch has conducted research to improve the understanding of metabolic complications of HIV, including cardiovascular disease. She has also explored potential treatment interventions for these complications which are grounded in health promotion, and her work has resulted in several publications and presentations. Katie was recently awarded the Excellence in Nursing Research Award by the Massachusetts American Nurses Association. Katie served as a National Health Service Corps Scholar and has worked in primary care as a nurse practitioner at the Boston Health Care for the Homeless Program. She is also a volunteer community educator at several HIV service organizations throughout Massachusetts, where she enjoys helping community members better understand how to prevent co-morbidities such as heart disease, diabetes, and dyslipidemia. Katie was the Project Manager for the REPRIEVE trial; a multicenter trial that has found that pitavastatin, a statin medication, prevented heart disease events among people with HIV. Katie also helped to start the Age Positively Program at MGH Infectious Disease Clinic, a program focused on the health of people aging with HIV. Throughout her experiences, Katie has been dedicated to HIV research and the role that nurses and nurse practitioners have in this area of practice.

CE Information

This activity offers 1.0 CE credit (0.5 pharmacology) to attendees.

Accredited by American Academy of CME, Inc..

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NPs and Nurses:

American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours
(0.5 Pharmacotherapeutic Contact Hours).

California
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.0 contact hours.

Physician Assistants

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 6, 2025. PAs should only claim credit commensurate with the extent of their participation.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other members of the care team will receive a certificate of participation.

Disclosures

Support

Support for this activity has been made possible through an educational grant from Gilead Sciences.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Educator/Planner Disclosures

Kathleen Fitch, MSN, FNP-BC: No relevant financial relationships to disclose.
Virginia Triant, MD, MPH: No relevant financial relationships to disclose.

Planning Team:

Jonathan Colasanti, MD; Courtney Fletcher, PharmD; Jose Gutierrez, PhD, FNP-BC; Asa E. Radix, MD, PhD, MPH; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Daiquiri Y. Robinson, MEd: No relevant financial relationships to disclose.
Roger Bedimo, MD, MS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Merck, Theratechnologies, Janssen, Shionogi; Grant/Research Support – Merck
William R. Short, MD, MPH: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences; Grant/Research Support – Gilead Sciences, Janssen*
H. Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Sarah Smith, MHS, PA-C, AAHIVS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Janssen, Merck; Speakers Bureau – ViiV Healthcare, Gilead Sciences, Janssen, Merck
*Relationship has ended.
This activity does not include information about off-label uses of approved agents and/or investigational agents.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy/ACTHIV® Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity